75 related articles for article (PubMed ID: 1743317)
1. Effects of vehicle supplementation on total estradiol absorption from a transdermal estradiol delivery system.
Smith RD; Robinson DE; Delignieres B; Albertson BD; Tomai TP; Zinaman MJ; Simon JA
Fertil Steril; 1991 Dec; 56(6):1029-33. PubMed ID: 1743317
[TBL] [Abstract][Full Text] [Related]
2. 17Beta-estradiol delivered by three different matrix patches 50 microg/day: a three way cross-over study in 21 postmenopausal women.
Rohr UD; Nauert C; Stehle B
Maturitas; 1999 Sep; 33(1):45-58. PubMed ID: 10585173
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of percutaneous estradiol: a crossover study using a gel and a transdermal system in comparison with oral micronized estradiol.
Scott RT; Ross B; Anderson C; Archer DF
Obstet Gynecol; 1991 May; 77(5):758-64. PubMed ID: 2014092
[TBL] [Abstract][Full Text] [Related]
4. The effects of ethanol on the clearance of estradiol in postmenopausal women.
Ginsburg ES; Walsh BW; Shea BF; Gao X; Gleason RE; Barbieri RL
Fertil Steril; 1995 Jun; 63(6):1227-30. PubMed ID: 7750592
[TBL] [Abstract][Full Text] [Related]
5. [Bioavailability of 17 beta-estradiol after transdermal administration--dependence on the patch system].
Schmolling J; Kusche J; van der Ven H; Schander K
Zentralbl Gynakol; 1998; 120(3):121-5. PubMed ID: 9556902
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of estradiol and of estrone during application of a new 7-day estradiol transdermal patch with active matrix.
Setnikar I; Rovati LC; Vens-Cappell B; Hilgenstock C
Arzneimittelforschung; 1998 Mar; 48(3):275-85. PubMed ID: 9553686
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of weekly transdermal estradiol controlled delivery system in postmenopausal Chinese.
Chen GS; Zhang MY; Wang Q; Ye JC
Zhongguo Yao Li Xue Bao; 1996 Sep; 17(5):407-10. PubMed ID: 9863160
[TBL] [Abstract][Full Text] [Related]
8. Plasma profiles of transdermal 17 beta-estradiol delivered by two different matrix patches. A four-way cross-over study in postmenopausal women.
Rohr UD; Ehrly AM; Kuhl H
Arzneimittelforschung; 1997 Jun; 47(6):761-7. PubMed ID: 9239456
[TBL] [Abstract][Full Text] [Related]
9. Comparative absorption and variability in absorption of estradiol from a transdermal gel and a novel matrix-type transdermal patch.
Järvinen A; Bäckström A; Elfström C; Viitanen A
Maturitas; 2001 Apr; 38(2):189-96. PubMed ID: 11306208
[TBL] [Abstract][Full Text] [Related]
10. Bioavailability of estradiol from two transdermal patches.
Setnikar I; Rovati LC; Vens-Cappell B; Hilgenstock C
Arzneimittelforschung; 1996 Mar; 46(3):307-10. PubMed ID: 8901155
[TBL] [Abstract][Full Text] [Related]
11. Comparison of pharmacokinetic profiles of a 17 beta-estradiol gel 0.6 mg/g (Gelestra) with a transdermal delivery system (Estraderm TTS 50) in postmenopausal women at steady state.
Paoletti AM; Pilia I; Nannipieri F; Bigini C; Melis GB
Maturitas; 2001 Dec; 40(3):203-9. PubMed ID: 11731181
[TBL] [Abstract][Full Text] [Related]
12. Comparison of steady state development and reduction of menopausal symptoms after oral or transdermal delivery of 17-β-estradiol in young healthy symptomatic menopausal women.
Rohr UD; Volko CD; Schindler AE
Horm Mol Biol Clin Investig; 2014 Jun; 18(3):123-36. PubMed ID: 25390008
[TBL] [Abstract][Full Text] [Related]
13. Half-life of estradiol in postmenopausal women.
Ginsburg ES; Gao X; Shea BF; Barbieri RL
Gynecol Obstet Invest; 1998; 45(1):45-8. PubMed ID: 9473164
[TBL] [Abstract][Full Text] [Related]
14. Long-term effects of transdermal estradiol with and without medroxyprogesterone acetate.
Pang SC; Greendale GA; Cedars MI; Gambone JC; Lozano K; Eggena P; Judd HL
Fertil Steril; 1993 Jan; 59(1):76-82. PubMed ID: 8419226
[TBL] [Abstract][Full Text] [Related]
15. Estradiol pharmacokinetics after transdermal application of patches to postmenopausal women: matrix versus reservoir patches.
Reginster JY; Donazzolo Y; Brion N; Lins R
Climacteric; 2000 Sep; 3(3):168-75. PubMed ID: 11910618
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of continuous once-a-week combination 17β-Estradiol/Low- or high-dose levonorgestrel transdermal delivery systems in postmenopausal women.
Karara AH; Harrison LI; Melikian AP; Poola N; Morrison D; Bourg D; Bourg L; Zurth C
J Clin Pharmacol; 2014 May; 54(5):520-7. PubMed ID: 24474034
[TBL] [Abstract][Full Text] [Related]
17. Effects of short-term transdermal estradiol administration on plasma levels of nitric oxide in postmenopausal women.
Cicinelli E; Ignarro LJ; Schönauer LM; Matteo MG; Galantino P; Balzano G
Fertil Steril; 1998 Jan; 69(1):58-61. PubMed ID: 9457933
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of estradiol and of estrone during repeated transdermal or oral administration of estradiol.
Setnikar I; Rovati LC; Vens-Cappell B; Hilgenstock C
Arzneimittelforschung; 1996 Aug; 46(8):766-73. PubMed ID: 9125276
[TBL] [Abstract][Full Text] [Related]
19. Acute effects of transdermal estradiol administration on plasma levels of nitric oxide in postmenopausal women.
Cicinelli E; Ignarro LJ; Lograno M; Matteo G; Falco N; Schonauer LM
Fertil Steril; 1997 Jan; 67(1):63-6. PubMed ID: 8986685
[TBL] [Abstract][Full Text] [Related]
20. Comparative serum estradiol profiles from a new once-a-week transdermal estradiol patch and a twice-a-week transdermal estradiol patch.
Harrison LI; Riedel DJ; Chang SF; Jacobson JP; Sellers JA; Kanniainen CM; Crowley JK; Hinderling PH
Ther Drug Monit; 1997 Feb; 19(1):37-42. PubMed ID: 9029744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
